BIND Biosciences

Bind Biosciences (BIND) is a biopharmaceutical company developing therapeutic targeted nanoparticles. Leveraging its proprietary Medicinal Nanoengineering™ platform, BIND will produce best in class drugs by drastically enhancing the performance of development candidates or marketed drugs. BIND’s current development efforts focus on oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics. Lead program BIND-014 targets a surface protein upregulated in solid tumors and is planned to enter clinical development by end 2010.

BIND was incorporated in 2007 in Cambridge, MA, based on the work of two pioneers in the field of therapeutic nanoparticles, Dr. Robert Langer (MIT) and Dr. Omid Farokhzad (Harvard Medical School).


Recent News

April 4, 2012
BIND Biosciences Presents Clinical Data on BIND-014 Promising Anti-tumor Effects in Patients with Advanced or Metastatic Cancers

 
October 27, 2011
BIND Announces New $47.25 Million Financing To Accelerate Multi-Product Pipeline

 
April 6, 2011
BIND Biosciences Receives 2011 Edison Award

 
February 23, 2011
BIND Biosciences named one of MIT's Technology Review 2011 TR50 - second year in a row

 
February 11, 2011
BIND Biosciences featured in the London Times

 
January 7, 2011
BIND Biosciences Initiates Phase 1 Clinical Study of BIND-014

 
June 29, 2010
BIND Biosciences Secures $12.4 Million Financing

 


Company Info
 
Country: USA
Industry:    LS
Sector: biotechnology
Status: Unrealized
Vehicle: Endeavour II LP


Key persons
 Scott Minick, CEO; Dr. Robert Langer, co-founder; Dr. Omid Farokhzad, co-founder


Company website
 www.bindbio.com


Endeavour Vision Team
 
Olivier Valdenaire
Sven Lingjaerde
© Endeavour Vision SA 2006-2012 Terms & Conditions